Ribonova Inc.
Mass spectrometry method and reagent kit for mapping modified nucleotides in human mitochondrial transfer RNA, plus a database of modification maps from healthy and diseased subjects
- Sector
- Biotech
- Total capital
- $1.8M
- Federal grants
- $1.5M
- 4 awards · 2015–2017
- 4.0× sector median 1 award
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- $299K
- 1 award · Health and Human S
- Rank in Biotech#271 of 4373
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Federal contractHealth and Human S · Igf::ot::igf Novel Mass Spectrometry Methods And Research Tools To Map Nucleotide Modifications In Cytosolic Transfer Rnas Form Cancer Cells (moonshot)$299K
- Federal grantHealth and Human S · Phase II · Development of novel research tools and a database for mapping human mitochondrial tRNA modifications by mass spectrometry$973K
- Federal grantHealth and Human S · Phase II · Development of novel research tools and a database for mapping human mitochondrial tRNA modifications by mass spectrometry$150K
- Federal grantHealth and Human S · Phase I · Novel mass spectrometry methods for profiling modified RNA nucleotides in the nervous system$177K
- Federal grantHealth and Human S · Phase I · Novel mass spectrometry methods for profiling modified RNA nucleotides in the nervous system$177K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing in Biotech · 4373 companies
Line = median- Federal contracts#271 · top 6%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 2- PendingMethods of Treating Mitochondrial DysfunctionUSPTOApplication 18794145
- PendingMethods of Treating Mitochondrial DysfunctionUSPTOApplication 17255508
Related companies, and why
- ADT PHARMACEUTICALS, LLCSimilar federal contract value in Biotech · $300K in contracts
- NECTAGEN INCSimilar federal contract value in Biotech · $300K in contracts
- HYLAPHARM LLCSimilar federal contract value in Biotech · $300K in contracts
- TREVIGEN, INC.Similar federal contract value in Biotech · $299K in contracts
- GLYCOHUB, INC.Similar federal contract value in Biotech · $298K in contracts
- CASTERBRIDGE PHARMACEUTICALS INCSimilar federal contract value in Biotech · $297K in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .